Novel coumarin-pyridazine hybrids as selective MAO-B inhibitors for the Parkinson’s disease therapy
Fernanda Rodríguez‐Enríquez, María Carmen Costas-Lago, Pedro Besada, Miguel Alonso-Pena, Iria Torres-Terán, Dolores Viña, José A. Fontenla, Mattia Sturlese, Stefano Moro, Elías Quezada, Carmen Terán
Topics & Concepts
ChemistryCoumarinPyridazineLipophilicityIn vivoRasagilinePharmacologyEnzymeIC50StereochemistryCombinatorial chemistryBiochemistryIn vitroParkinson's diseaseDiseaseOrganic chemistryBiologyPathologyMedicineBiotechnologyParkinson's Disease Mechanisms and TreatmentsClick Chemistry and ApplicationsCholinesterase and Neurodegenerative Diseases